Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 2183 results for guidelines

  1. Mortality: cardiovascular disease (IND280)

    This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  2. Mortality: respiratory (IND281)

    This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  3. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  4. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  5. Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  6. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

  7. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  8. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs

  9. SEM Scanner 200 for preventing pressure ulcers (HTG556)

    Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.

  10. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  11. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  12. Implanting a baroreceptor stimulation device for resistant hypertension

    In development Reference number: GID-IP1180 Expected publication date: TBC

  13. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

  14. Podcasts

    February 2026 The asthma guideline – one year on In this episode of NICE Talks, we learn the impact of the joint asthma...

  15. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.